Cargando…

Inhibition of β-Catenin to Overcome Endocrine Resistance in Tamoxifen-Resistant Breast Cancer Cell Line

BACKGROUND: The β-catenin signaling is important in cell growth and differentiation and is frequently dysregulated in various cancers. The most well-known mechanism of endocrine resistance is cross-talk between the estrogen receptor (ER) and other growth factor signaling, such as phosphatidylinosito...

Descripción completa

Detalles Bibliográficos
Autores principales:	Won, Hye Sung, Lee, Kyung Mee, Oh, Ju Eon, Nam, Eun Mi, Lee, Kyoung Eun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873201/ https://www.ncbi.nlm.nih.gov/pubmed/27196739 http://dx.doi.org/10.1371/journal.pone.0155983

Ejemplares similares

Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer
por: Woo, Hye In, et al.
Publicado: (2017)

Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells
por: Moon, Seo Yun, et al.
Publicado: (2021)

Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
por: Kang, Da Hyun, et al.
Publicado: (2020)

Rhodacyanine Derivative Selectively Targets Cancer Cells and Overcomes Tamoxifen Resistance
por: Koren, John, et al.
Publicado: (2012)

Targeting β-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations
por: Moon, Jai-Hee, et al.
Publicado: (2019)

Correction: Rhodacyanine Derivative Selectively Targets Cancer Cells and Overcomes Tamoxifen Resistance
por: Koren, John, et al.
Publicado: (2012)

Identification of potential target genes of honokiol in overcoming breast cancer resistance to tamoxifen
por: Hermawan, Adam, et al.
Publicado: (2022)

Induction of methionine adenosyltransferase 2A in tamoxifen-resistant breast cancer cells
por: Phuong, Nguyen Thi Thuy, et al.
Publicado: (2015)

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
por: Yun, Mi Ran, et al.
Publicado: (2019)

Targeting BIG3–PHB2 interaction to overcome tamoxifen resistance in breast cancer cells
por: Yoshimaru, Tetsuro, et al.
Publicado: (2013)

ECM1 is associated with endocrine resistance in ER(+) breast cancers
por: Lee, Tae Won, et al.
Publicado: (2022)

Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
por: D’Souza, Anishka, et al.
Publicado: (2018)

Inhibition of tamoxifen's therapeutic effects by emodin in estrogen receptor-positive breast cancer cell lines
por: Kim, Yun Gyoung, et al.
Publicado: (2019)

A Therapeutic Strategy for Chemotherapy-Resistant Gastric Cancer via Destabilization of Both β-Catenin and RAS
por: Ryu, Won-Ji, et al.
Publicado: (2019)

Cosuppression of NF-κB and AICDA Overcomes Acquired EGFR-TKI Resistance in Non-Small Cell Lung Cancer
por: Yeo, Min-Kyung, et al.
Publicado: (2022)

Circumvention of Daunorubicin Resistance by a New Tamoxifen Derivative, Toremifene, in Multidrug‐resistant Cell Line
por: Urasaki, Yoshimasa, et al.
Publicado: (1994)

Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer
por: Han, Wonshik, et al.
Publicado: (2006)

Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
por: Na, Yoo Jin, et al.
Publicado: (2021)

Fibronectin expression is upregulated by PI-3K/Akt activation in tamoxifen-resistant breast cancer cells
por: You, Daeun, et al.
Publicado: (2017)

Tamoxifen Resistance in Breast Cancer
por: Chang, Minsun
Publicado: (2012)

Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines
por: KIM, JINKYOUNG, et al.
Publicado: (2016)

Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells
por: Woo, Yu Mi, et al.
Publicado: (2015)

A novel C-terminal heat shock protein 90 inhibitor that overcomes STAT3-Wnt-β-catenin signaling-mediated drug resistance and adverse effects
por: Lee, Ho Jin, et al.
Publicado: (2022)

Mechanisms of methotrexate resistance in osteosarcoma cell lines and strategies for overcoming this resistance
por: WANG, JIANJUN, et al.
Publicado: (2015)

MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit
por: Løkkegaard, Sanne, et al.
Publicado: (2021)

Identification of Tamoxifen-Resistant Breast Cancer Cell Lines and Drug Response Signature
por: Guan, Qingzhou, et al.
Publicado: (2020)

Overcoming Resistance to Endocrine Therapy in Breast Cancer: New Approaches to a Nagging Problem
por: Luqmani, Yunus A., et al.
Publicado: (2016)

MTA1 is a novel regulator of autophagy that induces tamoxifen resistance in breast cancer cells
por: Lee, Min-Ho, et al.
Publicado: (2018)

Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine
por: Wang, Yuntao, et al.
Publicado: (2021)

COVID-19 Vaccination for Endocrine Patients: A Position Statement from the Korean Endocrine Society
por: Ku, Cheol Ryong, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society
por: Kwon, Hyemi, et al.
Publicado: (2022)

Pancreatic Endocrine Tumors: A Report on a Patient Treated with Sorafenib
por: Jeong, Hee Kyoung, et al.
Publicado: (2011)

Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer
por: Jiang, Cen, et al.
Publicado: (2023)

RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity
por: Barua, David, et al.
Publicado: (2023)

Exendin-4 Inhibits Hepatic Lipogenesis by Increasing β-Catenin Signaling
por: Seo, Mi Hae, et al.
Publicado: (2016)

Tamoxifen resistance and adjuvant hormone therapy
por: Howell, A
Publicado: (2005)

Leishmania is not prone to develop resistance to tamoxifen
por: Coelho, Adriano C., et al.
Publicado: (2015)

Tamoxifen Resistance: Emerging Molecular Targets
por: Rondón-Lagos, Milena, et al.
Publicado: (2016)

Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines.
por: McClay, E. F., et al.
Publicado: (1994)

Molecular Mechanism of SAHA on Regulation of Autophagic Cell Death in Tamoxifen-Resistant MCF-7 Breast Cancer Cells
por: Lee, Young Ju, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_r80a4i6qd0gjmkvuje9je21h4v